Kenneth Ian Mills

List of Publications by Year
in descending order

167	4,988	117625	106344
papers	citations	34 h-index	65 g-index

174	174	174	7940
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors. Cancer Research, 2022, 82, 819-830.	0.9	16
2	Comparison of SARS-CoV-2 Evolution in Paediatric Primary Airway Epithelial Cell Cultures Compared with Vero-Derived Cell Lines. Viruses, 2022, 14, 325.	3.3	5
3	Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signature. Blood Advances, 2021, 5, 1059-1068.	5.2	11
4	Survivinâ€™ Acute Myeloid Leukaemiaâ€”A Personalised Target for inv(16) Patients. International Journal of Molecular Sciences, 2021, 22, 10482.	4.1	4
5	Significance of NPM1 Gene Mutations in AML. International Journal of Molecular Sciences, 2021, 22, 10040.	4.1	18
6	Multiplex Screening for Interacting Compounds in Paediatric Acute Myeloid Leukaemia. International Journal of Molecular Sciences, 2021, 22, 10163.	4.1	2
7	Identification of Genes Whose Expression Overlaps Age Boundaries and Correlates with Risk Groups in Paediatric and Adult Acute Myeloid Leukaemia. Cancers, 2020, 12, 2769.	3.7	6
8	A compound combination screening approach with potential to identify new treatment options for paediatric acute myeloid leukaemia. Scientific Reports, 2020, 10, 18514.	3.3	5
9	Chronic loss of STAG2 leads to altered chromatin structure contributing to de-regulated transcription in AML. Journal of Translational Medicine, 2020, 18, 339.	4.4	15
10	Post-diagnostic antipsychotic use and cancer mortality: a population based cohort study. BMC Cancer, 2020, 20, 804.	2.6	8
11	New targets for therapy: antigen identification in adults with B-cell acute lymphoblastic leukaemia. Cancer Immunology, Immunotherapy, 2020, 69, 867-877.	4.2	3
12	Serum profiling identifies ibrutinib as a treatment option for young adults with Bâ€cell acute lymphoblastic leukaemia. British Journal of Haematology, 2020, 189, 500-512.	2.5	4
13	Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia. Haematologica, 2020, 105, 448-456.	3.5	64
14	Methylation age as a correlate for allele burden, disease status, and clinical response in myeloproliferative neoplasm patients treated with vorinostat. Experimental Hematology, 2019, 79, 26-34.	0.4	8
15	Altered splicing and cytoplasmic levels of tRNA synthetases in SF3B1-mutant myelodysplastic syndromes as a therapeutic vulnerability. Scientific Reports, 2019, 9, 2678.	3.3	12
16	Pathways, Processes, and Candidate Drugs Associated with a Hoxa Cluster-Dependency Model of Leukemia. Cancers, 2019, 11, 2036.	3.7	5
17	Relevance of TP53 for CLL diagnostics. Journal of Clinical Pathology, 2019, 72, 343-346.	2.0	10
18	The histone deacetylase inhibitor Romidepsin induces as a cascade of differential gene expression and altered histone H3K9 marks in myeloid leukaemia cells. Oncotarget, 2019, 10, 3462-3471.	1.8	8

#	Article	IF	Citations
19	A combined connectivity mapping and pharmacoepidemiology approach to identify existing medications with breast cancer causing or preventing properties. Pharmacoepidemiology and Drug Safety, 2018, 27, 78-86.	1.9	13
20	Compositional analysis gives insight into leukaemia cell lines expression profiles compared to those within patient subâ€groups. British Journal of Haematology, 2018, 181, 847-851.	2.5	0
21	The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms. Journal of Translational Medicine, 2018, 16, 360.	4.4	50
22	Selective serotonin reuptake inhibitor use and breast cancer survival: a population-based cohort study. Breast Cancer Research, 2018, 20, 4.	5.0	33
23	Living Long and Aging Well. , 2018, , 137-152.		0
24	Identification of survivin as a promising target for the immunotherapy of adult B-cell acute lymphoblastic leukemia. Oncotarget, 2018, 9, 3853-3866.	1.8	13
25	Relationship between HUWE1 Mutation and Functionality in Multiple Myeloma. Blood, 2018, 132, 4512-4512.	1.4	0
26	The Potential of Using DNA Damage Repair Deficiency As a Biomarker for Cytarabine Response in AML Patients. Blood, 2018, 132, 2812-2812.	1.4	0
27	Identifying Combination Therapies Targeting Apoptosis Pathways in Pediatric Acute Myeloid Leukemia (CAuSAL Study). Blood, 2018, 132, 2731-2731.	1.4	0
28	Epigenetics in Myeloproliferative Neoplasms. Journal of Cellular and Molecular Medicine, 2017, 21, 1660-1667.	3.6	29
29	An integrated meta-analysis approach to identifying medications with potential to alter breast cancer risk through connectivity mapping. BMC Bioinformatics, 2017, 18, 581.	2.6	5
30	Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy. Oncotarget, 2017, 8, 51429-51446.	1.8	30
31	Erythropoietin drives breast cancer progression by activation of its receptor EPOR. Oncotarget, 2017, 8, 38251-38263.	1.8	24
32	Integrated analysis of the molecular action of Vorinostat identifies epi-sensitised targets for combination therapy. Oncotarget, 2017, 8, 67891-67903.	1.8	4
33	GATA2 regulates the erythropoietin receptor in t(12;21) ALL. Oncotarget, 2017, 8, 66061-66074.	1.8	7
34	A molecular signature of dormancy in CD34+CD38- acute myeloid leukaemia cells. Oncotarget, 2017, 8, 111405-111418.	1.8	13
35	Polycomb protein RING1A limits hematopoietic differentiation in myelodysplastic syndromes. Oncotarget, 2017, 8, 115002-115017.	1.8	6
36	A childhood acute lymphoblastic leukemia genome-wide association study identifies novel sex-specific risk variants. Medicine (United States), 2016, 95, e5300.	1.0	20

#	Article	IF	Citations
37	Persistence of <scp>DNMT</scp>3A does not influence clinical outcome in acute myeloid leukaemia. British Journal of Haematology, 2016, 175, 185-186.	2.5	1
38	QUADrATiC: scalable gene expression connectivity mapping for repurposing FDA-approved therapeutics. BMC Bioinformatics, 2016, 17, 198.	2.6	25
39	GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways. Journal of Hematology and Oncology, 2016, 9, 5.	17.0	10
40	Inter-Laboratory Evaluation of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia. Molecular Diagnosis and Therapy, 2016, 20, 457-461.	3.8	9
41	Living long and ageing well: is epigenomics the missing link between nature and nurture?. Biogerontology, 2016, 17, 33-54.	3.9	25
42	Low-dose salinomycin induces anti-leukemic responses in AML and MLL. Oncotarget, 2016, 7, 73448-73461.	1.8	11
43	Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia. Oncotarget, 2016, 7, 6609-6619.	1.8	16
44	Addiction toRunx1is partially attenuated by loss of p53 in the EÎ¼-Myc lymphoma model. Oncotarget, 2016, 7, 22973-22987.	1.8	9
45	Loss of Function Cohesin Complex Gene Mutations Create Neomorphic Cell States Advantageous to Oncogenesis. Blood, 2016, 128, 1564-1564.	1.4	0
46	Infrequent Expression of the Cancer-Testis Antigen, PASD1, in Ovarian Cancer. Biomarkers in Cancer, 2015, 7, BIC.S28378.	3.6	9
47	Deregulation of Genes Related to Iron and Mitochondrial Metabolism in Refractory Anemia with Ring Sideroblasts. PLoS ONE, 2015, 10, e0126555.	2.5	21
48	Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis. PLoS ONE, 2015, 10, e0140483.	2.5	13
49	Repurposing medicinal compounds for blood cancer treatment. Annals of Hematology, 2015, 94, 1267-1276.	1.8	27
50	DEK oncogene expression during normal hematopoiesis and in Acute Myeloid Leukemia (AML). Blood Cells, Molecules, and Diseases, 2015, 54, 123-131.	1.4	14
51	Epigenetic Gene Mutations Impact on Outcome in Acute Myeloid Leukaemia. EBioMedicine, 2015, 2, 487-488.	6.1	0
52	Up-regulatedMSI2is associated with more aggressive chronic myeloid leukemia. Leukemia and Lymphoma, 2015, 56, 2105-2113.	1.3	23
53	Differential expression ofSHP-1in chronic myeloid leukemia. Leukemia and Lymphoma, 2015, 56, 1547-1549.	1.3	3
54	Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia. Blood, 2015, 125, 2985-2994.	1.4	42

#	Article	IF	Citations
55	The impact of next generation sequencing technologies on haematological research â€“ A review. Pathogenesis, 2015, 2, 9-16.	0.8	19
56	Conditional Deletion of the Hoxa Cluster in MLL-AF9 Is Incompatible with Leukemia Maintenance. Blood, 2015, 126, 3630-3630.	1.4	0
57	Distinct poor prognostic subgroups of acute myeloid leukaemia, FLT3-ITD and P-glycoprotein-positive, have contrasting levels of FOXO1. Leukemia Research, 2014, 38, 131-137.	0.8	8
58	Relationship between genome and epigenome - challenges and requirements for future research. BMC Genomics, 2014, 15, 487.	2.8	24
59	Mutational spectrum defines primary and secondary myelofibrosis. Haematologica, 2014, 99, 2-3.	3.5	10
60	Identification of Gene Expressionâ€“Based Prognostic Markers in the Hematopoietic Stem Cells of Patients With Myelodysplastic Syndromes. Journal of Clinical Oncology, 2013, 31, 3557-3564.	1.6	45
61	Prognostic and therapeutic relevance of câ€<scp>FLIP</scp> in acute myeloid leukaemia. British Journal of Haematology, 2013, 160, 188-198.	2.5	39
62	Altered methylation levels in elderly acute myeloid leukaemia patients compared to elderly well individuals. British Journal of Haematology, 2013, 161, 294-296.	2.5	3
63	High and low, but not intermediate, <scp>PRAME</scp> expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation. British Journal of Haematology, 2013, 162, 282-285.	2.5	12
64	Entinostat Prevents Leukemia Maintenance in a Collaborating Oncogene-Dependent Model of Cytogenetically Normal Acute Myeloid Leukemia. Stem Cells, 2013, 31, 1434-1445.	3.2	30
65	Oncogenic roles of <scp>PRL</scp>â€3 in <scp>FLT</scp>3â€<scp>ITD</scp> induced acute myeloid leukaemia. EMBO Molecular Medicine, 2013, 5, 1351-1366.	6.9	44
66	Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts. Haematologica, 2013, 98, 576-583.	3.5	9
67	HOXA/PBX3 knockdown impairs growth and sensitizes cytogenetically normal acute myeloid leukemia cells to chemotherapy. Haematologica, 2013, 98, 1216-1225.	3.5	39
68	Validation of Next Generation Sequencing Technologies in Comparison to Current Diagnostic Gold Standards for BRAF, EGFR and KRAS Mutational Analysis. PLoS ONE, 2013, 8, e69604.	2.5	94
69	The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories. Blood, 2013, 122, 743-743.	1.4	6
70	A critical appraisal of tools available for monitoring epigenetic changes in clinical samples from patients with myeloid malignancies. Haematologica, 2012, 97, 1380-1388.	3.5	20
71	Elevated <scp>TRIB</scp>2 with <scp>NOTCH</scp>1 activation in paediatric/adult <scp>T</scp>â€<scp>ALL</scp>. British Journal of Haematology, 2012, 158, 626-634.	2.5	31
72	Screening for miRNA Expression Changes Using Quantitative PCR (Q-PCR). Methods in Molecular Biology, 2012, 863, 293-302.	0.9	3

#	Article	IF	Citations
73	Detection and Analysis of DNA Methylation by Pyrosequencing. Methods in Molecular Biology, 2012, 863, 281-292.	0.9	7
74	Detecting DNA Methylation Using the Methylated CpG Island Amplification and Microarray Technique. Methods in Molecular Biology, 2012, 863, 329-339.	0.9	2
75	Microarray for Epigenetic Changes: Gene Expression Arrays. Methods in Molecular Biology, 2012, 863, 319-328.	0.9	6
76	Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes. Annals of Hematology, 2012, 91, 1221-1233.	1.8	37
77	Differential TERT promoter methylation and response to 5â€²-azaâ€²-2â€²-deoxycytidine in acute myeloid leukemia cell lines: TERT expression, telomerase activity, telomere length, and cell death. Genes Chromosomes and Cancer, 2012, 51, 768-780.	2.8	26
78	Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nature Medicine, 2012, 18, 605-611.	30.7	584
79	New prognostic markers, determined using gene expression analyses, reveal two distinct subtypes of chronic myelomonocytic leukaemia patients. British Journal of Haematology, 2012, 157, 347-356.	2.5	8
80	The Interlaboratory Robustness of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses of Hematological Malignancies Performed by an International Network Involving 26 Laboratories. Blood, 2012, 120, 1399-1399.	1.4	6
81	Identifying an Acetylation Signature Following Vorinostat Treatment in AML. Blood, 2012, 120, 1291-1291.	1.4	0
82	Arrested Differentiation in Acute Myeloid Leukemia (AML) with Silenced Ankyrin Repeat and SOCS Box Protein 3 (ASB3) Expression. Blood, 2012, 120, 1232-1232.	1.4	0
83	Differential Expression of SHP-1 Levels in Chronic Phase and Advanced Disease CML and in AML Patients. Blood, 2012, 120, 1449-1449.	1.4	8
84	Epigenetic Silencing of BCL2, ETS1, IL27RA and DICER1 in Low-Risk MDS Patients. Blood, 2012, 120, 1704-1704.	1.4	0
85	Identification of Gene Expression Based Prognostic Markers in the Hematopoietic Stem Cells of Patients with Myelodysplastic Syndromes. Blood, 2012, 120, 3857-3857.	1.4	0
86	Gene expression profiling in MDS and AML: potential and future avenues. Leukemia, 2011, 25, 909-920.	7.2	64
87	Characterisation of Genome-Wide PLZF/RARA Target Genes. PLoS ONE, 2011, 6, e24176.	2.5	22
88	Pim2 cooperates with PML-RARÎ± to induce acute myeloid leukemia in a bone marrow transplantation model. Blood, 2010, 115, 4507-4516.	1.4	12
89	Molecular genetics. , 2010, , 90-110.		1
90	Identification of Gene Networks Associated with Acute Myeloid Leukemia by Comparative Molecular Methylation and Expression Profiling. Biomarkers in Cancer, 2010, 2, BIC.S3185.	3.6	4

#	Article	IF	Citations
91	Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Subclassification of Leukemia: Report From the International Microarray Innovations in Leukemia Study Group. Journal of Clinical Oncology, 2010, 28, 2529-2537.	1.6	567
92	Hoxa6 potentiates short-term hemopoietic cell proliferation and extended self-renewal. Experimental Hematology, 2009, 37, 322-333.e3.	0.4	25
93	Elevated expression of the leukemia-associated antigen SSX2IP predicts survival in acute myeloid leukemia patients who lack detectable cytogenetic rearrangements. Blood, 2009, 113, 1203-1204.	1.4	27
94	Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. Blood, 2009, 114, 1063-1072.	1.4	152
95	Comprehensive genomic screens identify a role for PLZF-RARÎ± as a positive regulator of cell proliferation via direct regulation of c-MYC. Blood, 2009, 114, 5499-5511.	1.4	53
96	Regulation of ABCB1 (p-glycoprotein) by the FOXO1 Transcription Factor in Acute Myeloid Leukemia.. Blood, 2009, 114, 589-589.	1.4	71
97	Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling. British Journal of Haematology, 2008, 141, 483-493.	2.5	46
98	An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase. British Journal of Haematology, 2008, 142, 802-807.	2.5	173
99	Nuclear factorâ€ºB as a potential therapeutic target for the novel cytotoxic agent LCâ€¹ in acute myeloid leukaemia. British Journal of Haematology, 2008, 143, 661-671.	2.5	20
100	WTX is rarely mutated in acute myeloid leukemia. Haematologica, 2008, 93, 947-948.	3.5	10
101	Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts. Haematologica, 2008, 93, 662-669.	3.5	82
102	Gene expression profiling for the diagnosis and prognosis of acute myeloid leukaemia. Frontiers in Bioscience - Landmark, 2008, Volume, 4605.	3.0	8
103	Comprehensive Genomic Screens Reveal Multiple Modes of Action of the PLZF-RAR-Î± Oncoprotein. Blood, 2008, 112, 686-686.	1.4	0
104	Azacytidine as a Maintenance Therapy in Elderly AML Progressively Demethylates CpG Sites within the p16 Gene. Blood, 2008, 112, 4466-4466.	1.4	2
105	RARÎ±-PLZF overcomes PLZF-mediated repression of CRABPI , contributing to retinoid resistance in t(11;17) acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 18694-18699.	7.1	62
106	Leukemia Associated Antigens: Their Dual Role as Biomarkers and Immunotherapeutic Targets for Acute Myeloid Leukemia. Biomarker Insights, 2007, 2, 117727190700200.	2.5	6
107	CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia, 2007, 21, 566-568.	7.2	168
108	Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia. Leukemia, 2007, 21, 2495-2505.	7.2	78

#	Article	IF	Citations
109	FUS expression alters the differentiation response to all-trans retinoic acid in NB4 and NB4R2 cells. British Journal of Haematology, 2007, 139, 94-97.	2.5	5
110	SSX2IP expression in acute myeloid leukaemia: an association with mitotic spindle failure in t(8;21), and cell cycle in t(15;17) patients. British Journal of Haematology, 2007, 140, 071119224223003-???.	2.5	18
111	Comparison of the survival implications of tumour-associated versus cancer-testis antigen expression in acute myeloid leukaemia. British Journal of Haematology, 2007, 136, 510-512.	2.5	5
112	Immunotherapy of myeloid leukaemia. Cancer Immunology, Immunotherapy, 2007, 56, 943-957.	4.2	15
113	PHF23: A Novel Erythropoietin-Induced Gene Associated with AML and MDS.. Blood, 2007, 110, 3178-3178.	1.4	0
114	Leukemia associated antigens: their dual role as biomarkers and immunotherapeutic targets for acute myeloid leukemia. Biomarker Insights, 2007, 2, 69-79.	2.5	6
115	The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases. Blood, 2006, 108, 3494-3503.	1.4	110
116	Novel observation of three FLT3 codons mutated in tandem in an elderly acute myeloid leukaemia patient. British Journal of Haematology, 2006, 132, 116-117.	2.5	3
117	The tumour antigens RAGE-1 and MGEA6 are expressed more frequently in the less lineage restricted subgroups of presentation acute myeloid leukaemia. British Journal of Haematology, 2006, 134, 238-239.	2.5	15
118	Consensus guidelines for microarray gene expression analyses in leukemia from three European leukemia networks. Leukemia, 2006, 20, 1385-1392.	7.2	47
119	The sensitivity of human cells expressing RUNX1-RUNX1T1 to chemotherapeutic agents. Leukemia, 2006, 20, 1883-1885.	7.2	2
120	An International Multi-Center Study To Define the Application of Microarrays in the Diagnosis and Subclassification of Leukemia (MILE Study): Interim Analysis Based on 1,889 Patients Achieves 95.4% Prediction Accuracy.. Blood, 2006, 108, 103-103.	1.4	3
121	Inhibition of Cellular Aminopeptidases as Novel Therapy for AML.. Blood, 2006, 108, 2588-2588.	1.4	0
122	NF Kappa B as a Therapeutic Target in AML.. Blood, 2006, 108, 2587-2587.	1.4	5
123	Rapid and sensitive detection of internal tandem duplication and activating loop mutations of FLT3. British Journal of Haematology, 2005, 130, 203-208.	2.5	11
124	Assessment of the cellular response to the induced expression of defensin sense and antisense cDNA in acute promyelocytic leukemia cell lines. Leukemia and Lymphoma, 2005, 46, 743-752.	1.3	1
125	Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood, 2005, 106, 3768-3776.	1.4	205
126	Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemia. Biochemical and Biophysical Research Communications, 2005, 333, 703-713.	2.1	32

#	Article	IF	Citations
127	Micro-Array and Protein Analyses Reveal a Preferential Autocrine VEGF Survival Loop in CD38+ Sub-Clones When Compared with CD38â^' Sub-Clones Derived from the Same CLL Patient.. Blood, 2005, 106, 180-180.	1.4	2
128	The Aurora Kinase Inhibitor AZD1152 Causes Perturbation of Cell Cycle Distribution in Cell Lines and Primary AML Samples.. Blood, 2005, 106, 2759-2759.	1.4	2
129	The Novel Anti-Leukemic Agent LC-1, Is Preferentially Cytotoxic in CLL Cells Derived from Poor Prognostic Subsets.. Blood, 2005, 106, 2981-2981.	1.4	0
130	NF Kappa B as a Therapeutic Target in AML.. Blood, 2005, 106, 2770-2770.	1.4	1
131	Methods For the Molecular Analysis of Cancer: An Overview. Molecular Biotechnology, 2003, 23, 167-170.	2.4	1
132	A Simple PCR/RFLP Analysis Can Differentiate Between Candida albicans, Aspergillus niger, and Aspergillus fumigatus. Molecular Biotechnology, 2003, 24, 229-232.	2.4	8
133	Molecular Analysis of Cancer: An Overview. , 2002, 68, 001-005.		0
134	Overview. , 2002, 200, 001-007.		5
135	Increased circulating normal and BCR-ABL+Ve progenitor numbers in Philadelphia chromosome-positive acute myeloid leukaemia. Leukemia Research, 2002, 26, 997-1005.	0.8	2
136	Increased heterozygosity for MHC class II lineages in newborn males. Genes and Immunity, 2002, 3, 263-269.	4.1	68
137	Ex vivo purging by adenoviral p53 gene therapy does not affect NOD-SCID repopulating activity of human CD34+ cells. Cancer Gene Therapy, 2001, 8, 936-947.	4.6	7
138	Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 70, 212-217.	1.9	79
139	Abnormalities of adherent layers grown from bone marrow of patients with myelodysplasia. British Journal of Haematology, 2000, 111, 853-862.	2.5	49
140	Differential display as an approach to study differentiation and differentiation therapy in AML. Hematological Oncology, 2000, 18, 129-140.	1.7	3
141	High FUS/TLS expression in acute myeloid leukaemia samples. British Journal of Haematology, 2000, 108, 316-321.	2.5	10
142	AnIn VivoandIn VitroComparison of the Effects of b2-a2 and b3-a2 p210BCR-ABLSplice Variants on Murine 32D Cells. Leukemia and Lymphoma, 2000, 37, 393-404.	1.3	7
143	Unravelling an HLA-DR Association in Childhood Acute Lymphoblastic Leukemia. Blood, 1999, 94, 694-700.	1.4	92
144	Inhibition of Mitochondrial Function in HL60 Cells Is Associated with an Increased Apoptosis and Expression of CD14. Biochemical and Biophysical Research Communications, 1999, 263, 294-300.	2.1	48

#	Article	IF	Citations
145	Unravelling an HLA-DR Association in Childhood Acute Lymphoblastic Leukemia. Blood, 1999, 94, 694-700.	1.4	21
146	c-myc locus amplification and the acquisition of trisomy 8 in the evolution of chronic myeloid leukaemia. Leukemia Research, 1998, 22, 899-903.	0.8	48
147	Identification of transcription factors expressed during ATRA -induced neutrophil differentiation of HL60 cells. British Journal of Haematology, 1998, 103, 87-92.	2.5	8
148	Identification of a retinoic acid responsive aldoketoreductase expressed in HL60 leukaemic cells. FEBS Letters, 1998, 440, 158-162.	2.8	18
149	FOCAL XANTHOGRANULOMATOUS PYELONEPHRITIS PRESENTING AS A RENAL TUMOR WITH VENA CAVAL THROMBUS. Journal of Urology, 1998, 160, 117-118.	0.4	13
150	p53 Mutations, Methylation and Genomic Instability in the Progression of Chronic Myeloid Leukaemia. Leukemia and Lymphoma, 1997, 26, 211-226.	1.3	32
151	Specificity of ribozymes against the bcr-abl mRNAs in vitro. Biochemical Society Transactions, 1996, 24, 409S-409S.	3.4	1
152	Increasing methylation of the calcitonin gene during disease progression in sequential samples from CML patients. Leukemia Research, 1996, 20, 771-775.	0.8	18
153	Influence of the major histocompatibility complex on age at onset of chronic lymphoid leukaemia. International Journal of Cancer, 1996, 65, 134-139.	5.1	36
154	DNA methylation: biology and significance. Blood Reviews, 1996, 10, 249-261.	5.7	38
155	Dielectrophoretic separation and enrichment of CD34+cell subpopulation from bone marrow and peripheral blood stem cells. Medical and Biological Engineering and Computing, 1995, 33, 235-237.	2.8	103
156	Changing p53 mutations with the evolution of chronic myeloid leukaemia from the chronic phase to blast crisis. Leukemia Research, 1995, 19, 519-525.	0.8	13
157	Human Major Histocompatibility Complex Contains Several Leukemia Susceptibility Genes. Leukemia and Lymphoma, 1994, 12, 211-222.	1.3	43
158	Homozygous MHC Genotypes and Longevity. Human Heredity, 1994, 44, 271-278.	0.8	16
159	The Relationship Between the Location of the Breakpoint Within the M-BCR and Clinical Parameters. Leukemia and Lymphoma, 1993, 11, 73-79.	1.3	4
160	Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis, 1992, 13, 1035-1038.	2.8	104
161	THIRD PARTY MEDIATED GRAFT REJECTION DESPITE IRRADIATION OF BLOOD PRODUCTS. British Journal of Haematology, 1992, 80, 251-252.	2.5	34
162	Correlation of M-bcr breakpoint with different chromosomal abnormalities in blast crisis Ph1-positive CML. Leukemia Research, 1991, 15, 999-1003.	0.8	4

#	Article	IF	Citations
163	CYTOGENETIC AND MOLECULAR ANALYSIS OF RELAPSE FOLLOWING BONE MARROW TRANSPLANTATION. British Journal of Haematology, 1990, 75, 631-632.	2.5	3
164	False-positive results with PCR to detect leukaemia-specific transcript. Lancet, The, 1990, 335, 1037-1038.	13.7	65
165	Isolation of Molecular Hybridisation Probes for Early Myeloid Lineage RNAs. Annals of the New York Academy of Sciences, 1987, 511, 308-317.	3.8	0
166	Protein migration from transplanted nuclei in Amoeba proteus I. The relation to the cell cycle and RNA migration, as studied by autoradiography. Experimental Cell Research, 1982, 142, 207-213.	2.6	1
167	Protein migration from transplanted nuclei in Amoeba proteus. II. An electrophoretic study. Experimental Cell Research, 1981, 136, 469-473.	2.6	7